Per Odin

17.0k total citations · 1 hit paper
243 papers, 9.0k citations indexed

About

Per Odin is a scholar working on Neurology, Epidemiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Per Odin has authored 243 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Neurology, 53 papers in Epidemiology and 34 papers in Cellular and Molecular Neuroscience. Recurrent topics in Per Odin's work include Parkinson's Disease Mechanisms and Treatments (199 papers), Neurological disorders and treatments (137 papers) and Restless Legs Syndrome Research (52 papers). Per Odin is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (199 papers), Neurological disorders and treatments (137 papers) and Restless Legs Syndrome Research (52 papers). Per Odin collaborates with scholars based in Sweden, Germany and United Kingdom. Per Odin's co-authors include К. Ray Chaudhuri, Angelo Antonini, Pablo Martínez‐Martín, Olle Lindvall, Peter Hagell, Björn Öbrink, Patrik Brundin, David J. Brooks, Håkan Widner and C. D. Marsden and has published in prestigious journals such as PLoS ONE, Development and Neurology.

In The Last Decade

Per Odin

236 papers receiving 8.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

2013 487 citations Per Odin, Angelo Antonini et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Per Odin	6.9k	2.2k	1.6k	1.1k	1.0k	243	9.0k
Mark Stacy	6.0k 0.9×	2.5k 1.1×	618 0.4×	1.1k 1.0×	781 0.8×	110	8.0k
Laura Marsh	5.4k 0.8×	1.7k 0.8×	1.1k 0.7×	2.4k 2.1×	723 0.7×	138	9.0k
James H. Bower	6.2k 0.9×	2.4k 1.1×	724 0.5×	881 0.8×	923 0.9×	151	9.5k
Mario Zappia	4.4k 0.6×	1.8k 0.8×	525 0.3×	959 0.8×	1.2k 1.2×	288	8.0k
William J. Weiner	9.2k 1.3×	3.5k 1.6×	1.3k 0.8×	2.0k 1.7×	1.1k 1.1×	263	14.1k
Kapil D. Sethi	5.3k 0.8×	1.7k 0.8×	997 0.6×	1.0k 0.9×	511 0.5×	149	7.1k
Eng‐King Tan	5.6k 0.8×	2.0k 0.9×	1.1k 0.7×	967 0.8×	1.8k 1.8×	293	8.3k
Christopher G. Goetz	4.1k 0.6×	1.6k 0.7×	274 0.2×	909 0.8×	597 0.6×	102	6.3k
Matthew Stern	8.3k 1.2×	2.2k 1.0×	828 0.5×	1.4k 1.2×	826 0.8×	68	10.3k
Roger Kurlan	4.1k 0.6×	2.2k 1.0×	615 0.4×	2.9k 2.5×	596 0.6×	194	9.6k

Countries citing papers authored by Per Odin

Since Specialization

Citations

This map shows the geographic impact of Per Odin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Odin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Odin more than expected).

Fields of papers citing papers by Per Odin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Odin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Odin. The network helps show where Per Odin may publish in the future.

Co-authorship network of co-authors of Per Odin

This figure shows the co-authorship network connecting the top 25 collaborators of Per Odin. A scholar is included among the top collaborators of Per Odin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Odin. Per Odin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Odin, Per, et al.. (2025). Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson’s Disease: A Swedish Study on Real-World Use and Costs. Neurology and Therapy. 14(5). 1845–1860.

Chaudhuri, К. Ray, Alexandra Rizos, Carmen Rodríguez‐Blázquez, et al.. (2025). Conversion between NMSS and MDS‐NMS in Parkinson's Disease. Movement Disorders. 40(5). 813–820. 1 indexed citations

Bergquist, Filip, Per Odin, Anders Johansson, et al.. (2024). Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease. European Journal of Neurology. 32(1). e16582–e16582. 3 indexed citations

Chaudhuri, К. Ray, Jean‐Philippe Azulay, Per Odin, et al.. (2024). Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study. Drugs - Real World Outcomes. 11(1). 1–11. 31 indexed citations

Löhle, Matthias, Wolfgang H. Jost, Florin Gandor, et al.. (2024). Intercultural Translation and Application of the German Version of King’s Parkinson’s Disease Pain Questionnaire in Fluctuating Parkinson’s Disease. Acta Neurologica Scandinavica. 2024(1). 3 indexed citations

Dahlström, Örjan, et al.. (2023). Time to workforce exit after a Parkinson’s disease diagnosis. npj Parkinson s Disease. 9(1). 72–72. 2 indexed citations

Odin, Per, et al.. (2023). Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration. Neuropharmacology. 237. 109630–109630. 4 indexed citations

Phokaewvarangkul, Onanong, Roongroj Bhidayasiri, Pedro Ruiz, et al.. (2023). Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations. Journal of Neural Transmission. 130(11). 1451–1462. 9 indexed citations

Fuskevåg, Ole‐Martin, Mathias Toft, Kristina Rosqvist, et al.. (2023). Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. European Journal of Neurology. 31(2). e16144–e16144. 10 indexed citations

10.

Löhle, Matthias, et al.. (2023). Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training. Acta Neurologica Scandinavica. 2023. 1–10. 2 indexed citations

11.

Fegg, Martin, Joaquim J. Ferreira, Per Odin, et al.. (2023). Meaning in Life in Late-Stage Parkinson’s Disease: Results from the Care of Late-Stage Parkinsonism Study (CLaSP) in Six European Countries. Journal of Religion and Health. 63(3). 2140–2154. 1 indexed citations

12.

Bergquist, Filip, M. Ehrnebo, Dag Nyholm, et al.. (2022). Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology. 99(10). e965–e976. 15 indexed citations

13.

Norlin, Jenny M., Ulf Persson, Daniel Oudin Åström, et al.. (2022). Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health‐Related Quality of Life. Movement Disorders Clinical Practice. 10(3). 392–398. 3 indexed citations

14.

Antonini, Angelo, Rajesh Pahwa, Per Odin, et al.. (2022). Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy. 11(1). 303–318. 10 indexed citations

15.

Rosqvist, Kristina, Peter Hagell, Susanne Iwarsson, Maria H Nilsson, & Per Odin. (2019). Satisfaction with Care in Late Stage Parkinson’s Disease. Parkinson s Disease. 2019. 1–10. 7 indexed citations

16.

Kader, Manzur, Stina B. Jonasson, Susanne Iwarsson, Per Odin, & Maria H Nilsson. (2018). Mobility device use in people with Parkinson's disease: A 3-year follow-up study. Acta Neurologica Scandinavica. 138(1). 70–77. 14 indexed citations

17.

Odin, Per, et al.. (2017). Device-Aided Treatment Strategies in Advanced Parkinson's Disease. International review of neurobiology. 132. 453–474. 40 indexed citations

18.

Catalán, María José, Angelo Antonini, Matilde Calopa, et al.. (2017). Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci. 8. 44–53. 10 indexed citations

19.

Rizos, Alexandra, Y. Naidu, Anthony H.V. Schapira, et al.. (2011). Pain in Parkinson's disease: Observational study of 225 patients. UCL Discovery (University College London). 2 indexed citations

20.

Vinge, Ellen, et al.. (1994). Pravidel kan ge lungförändringar. Aktivitetstecken och viktnedgång ingår i bilden. Läkartidningen. 91(45). 8–4116.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact